In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Oramed Pharmaceuticals (ORMP – Research Report), with a price target of $32.00. The company’s shares closed last Friday at $12.03.
According to TipRanks, Selvaraju is an analyst with an average return of -30.2% and a 21.31% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Synlogic, Axsome Therapeutics, and Verona Pharma.
Currently, the analyst consensus on Oramed Pharmaceuticals is a Moderate Buy with an average price target of $32.00.
See today’s best-performing stocks on TipRanks >>
ORMP market cap is currently $470.6M and has a P/E ratio of -12.92.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in Jerusalem, Israel.
Read More on ORMP:
